Lv3
374 积分 2023-02-13 加入
Regulatory toxicology considerations for the development of inhaled pharmaceuticals
23小时前
已完结
Symposium Summary
23小时前
已完结
The spectrum of low-renin hypertension
7天前
已完结
Three ‘E’ challenges for siRNA drug development
17天前
已完结
Dual-action obesity drug rewires brain circuits for appetite
20天前
已完结
Signals for nausea and emesis: Implications for models of upper gastrointestinal diseases
20天前
已完结
CHF6001 II: A Novel Phosphodiesterase 4 Inhibitor, Suitable for Topical Pulmonary Administration—In Vivo Preclinical Pharmacology Profile Defines a Potent Anti-Inflammatory Compound with a Wide Therapeutic Window
26天前
已完结
CHF6001 I: A Novel Highly Potent and Selective Phosphodiesterase 4 Inhibitor with Robust Anti-Inflammatory Activity and Suitable for Topical Pulmonary Administration
27天前
已完结
Identification and utility exploration of a highly potent and long-acting bullfrog GLP-1 analogue in GLP-1 and amylin combination therapy
3个月前
已完结
Oral Muvalaplin for Lowering of Lipoprotein(a)
3个月前
已完结
皖公网安备34019202002308
